[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-001", "question": "A 54-year-old man with decompensated alcoholic cirrhosis (MELD-Na 29) is intubated for acute variceal hemorrhage and started on norepinephrine for hemorrhagic shock. Despite volume resuscitation, blood products, and endoscopic band ligation, he requires increasing vasopressor doses. Continuous renal replacement therapy is initiated for worsening azotemia and hyperkalemia. His MAP is 62 mm Hg on norepinephrine 0.24 mcg/kg/min and vasopressin 0.03 units/min. Lactate is 5.1 mmol/L; pH 7.28; ScvO2 76%. Bedside echo shows hyperdynamic LV function, small underfilled LV, and collapsible IVC. CVP is 4 mm Hg. You are considering adding a third agent. Which vasopressor strategy is most appropriate now?", "options": ["Add epinephrine infusion targeting higher MAP (70-75 mm Hg)", "Add low-dose dobutamine to improve splanchnic perfusion", "Add angiotensin II infusion while maintaining current MAP target", "Increase vasopressin above 0.04 units/min to exploit V1 receptor effect", "Switch norepinephrine to phenylephrine to minimize beta-adrenergic effects"], "answer": "C", "answer_index": 2, "explanation": "He has vasodilatory shock in advanced cirrhosis with catecholamine-resistant hypotension despite adequate volume; angiotensin II is reasonable as a third-line agent in catecholamine-refractory vasodilatory shock and has emerging use in hepatorenal-type circulatory failure. Epinephrine would increase lactate and myocardial oxygen demand without addressing RAAS dysregulation; high-dose vasopressin increases ischemia risk, phenylephrine may worsen gut perfusion, and dobutamine is not indicated with hyperdynamic LV and adequate ScvO2.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has decompensated alcoholic cirrhosis with refractory shock despite aggressive management. He is on norepinephrine and vasopressin, with a MAP of 62 mm Hg, but still has evidence of hypoperfusion (lactate 5.1 mmol/L, pH 7.28). The bedside echo shows a hyperdynamic LV with a small, underfilled LV and collapsible IVC, suggesting persistent hypovolemia or inadequate preload despite CVP of 4 mm Hg.\n\nLet's analyze the options:\n\nA. Adding epinephrine targeting a higher MAP (70-75 mm Hg) might be considered, but epinephrine has significant beta-adrenergic effects which could increase myocardial oxygen demand and potentially worsen myocardial ischemia in a patient with cirrhosis. While it can increase MAP, it might not be the most targeted approach for improving splanchnic perfusion.\n\nB. Adding low-dose dobutamine to improve splanchnic perfusion is a reasonable consideration. Dobutamine is an inotrope with some vasodilatory properties, which can improve cardiac output and potentially enhance perfusion to vital organs, including the splanchnic circulation, which is crucial in cirrhosis. The hyperdynamic LV function suggests that contractility might not be the primary issue, but improving cardiac output and thus splanchnic flow could be beneficial.\n\nC. Adding angiotensin II infusion while maintaining the current MAP target is a strong contender. Angiotensin II is a potent vasopressor that acts independently of adrenergic receptors and is effective in patients with septic shock refractory to other vasopressors. In cirrhosis, the renin-angiotensin-aldosterone system is often activated, but exogenous angiotensin II can still be effective in raising blood pressure and improving perfusion, especially when other agents are failing. The current MAP target of 62 mm Hg might be insufficient given the ongoing hypoperfusion. Angiotensin II can help achieve higher MAP targets and improve organ perfusion.\n\nD. Increasing vasopressin above 0.04 units/min to exploit V1 receptor effect is a possibility, as higher doses of vasopressin can have more potent vasoconstrictive effects. However, the patient is already on vasopressin, and increasing it further might not be as effective as adding a different mechanism of action, especially if there's some degree of vasopressin resistance.\n\nE. Switching norepinephrine to phenylephrine to minimize beta-adrenergic effects is not ideal. Phenylephrine is a pure alpha-agonist and would not address the potential need for inotropic support or improved cardiac output, which might be contributing to the hypoperfusion. Furthermore, in a hyperdynamic state, relying solely on alpha-agonism might not be sufficient.\n\nConsidering the patient's refractory shock, the presence of hypoperfusion despite adequate MAP, and the limitations of other agents, angiotensin II offers a distinct mechanism of action that can be effective in this scenario. While dobutamine could improve splanchnic perfusion, the primary issue appears to be inadequate systemic perfusion leading to organ dysfunction. Angiotensin II directly addresses the vasodilation and refractoriness to other vasopressors. The current MAP target might also be too low given the severity of the shock.\n\nHowever, re-evaluating the echo findings: \"small underfilled LV, and collapsible IVC. CVP is 4 mm Hg.\" This strongly suggests ongoing hypovolemia or inadequate preload. While vasopressors are necessary, addressing the preload deficit is paramount. The question asks for the *most appropriate* vasopressor strategy.\n\nLet's reconsider the options in light of the preload deficit.\nA. Epinephrine might increase preload demand.\nB. Dobutamine could improve cardiac output, but if preload is severely limited, its effectiveness will be blunted.\nC. Angiotensin II would increase MAP, but if the underlying issue is preload, it might not resolve the hypoperfusion.\nD. Increasing vasopressin might not address the preload issue.\nE. Phenylephrine would not improve cardiac output.\n\nThe patient is described as \"despite volume resuscitation.\" However, the echo findings are very suggestive of persistent hypovolemia. If preload is not optimized, vasopressors will be less effective. The question asks for a *vasopressor strategy*.\n\nLet's assume that volume resuscitation has been pushed as far as reasonable given the cirrhosis and potential for fluid overload. In this context, the persistent hypoperfusion despite vasopressors points towards a need for a more potent or differently acting vasopressor. Angiotensin II is known to be effective in refractory shock, including septic shock, and can help achieve higher MAP targets. Given the MELD-Na of 29, this patient is critically ill.\n\nHowever, the echo findings of a small, underfilled LV and collapsible IVC are very strong indicators of inadequate preload. While the question asks about a vasopressor strategy, it's important to consider the overall management. If preload is truly the limiting factor, then further volume administration (if safe) or optimizing venous return would be key. But assuming further volume is not an option or is insufficient, we need to choose the best vasopressor.\n\nLet's re-examine the options with the understanding that the patient is still hypoperfused.\nAngiotensin II (C) is a potent vasopressor that can raise MAP and improve perfusion in refractory shock. It acts via the renin-angiotensin system, which is often dysregulated in cirrhosis. Its efficacy in refractory shock is well-documented.\n\nDobutamine (B) could improve cardiac output and splanchnic perfusion, but if the LV is truly underfilled, its effectiveness might be limited.\n\nThe question is tricky because the echo findings point strongly to preload issues, but the options are all vasopressor strategies. If we must choose a vasopressor strategy, and assuming preload optimization has been done to the extent possible, then Angiotensin II is a strong choice for refractory shock.\n\nLet's consider the possibility that the \"small underfilled LV\" and \"collapsible IVC\" are relative findings in a hyperdynamic circulation, and the primary problem is persistent vasodilation and hypoperfusion. In this scenario, a potent vasopressor like Angiotensin II would be appropriate.\n\nConsidering the options again, and the fact that the patient is on two vasopressors and still hypoperfused, adding a third agent with a different mechanism is logical. Angiotensin II is a potent agent for refractory shock.\n\nFinal consideration: The patient has a MAP of 62 mm Hg, which is below the typical target for shock resuscitation (often 65-70 mm Hg or higher in specific populations). Angiotensin II can help achieve higher MAP targets.\n\nLet's assume the question implies that further volume resuscitation is either not possible or has been maximized. In that context, Angiotensin II is a strong choice for refractory shock.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-002", "question": "A 63-year-old woman with a history of JAK2-positive polycythemia vera treated with hydroxyurea for 9 years presents with 3 months of progressive fatigue, 7-kg weight loss, early satiety, and drenching night sweats. Exam shows marked splenomegaly 12 cm below the costal margin. CBC: Hgb 9.1 g/dL, MCV 96 fL, WBC 18,000/µL with left shift, platelets 110,000/µL. Peripheral smear reveals tear-drop cells, nucleated RBCs, and leukoerythroblastosis. LDH is elevated; uric acid is high. Bone marrow aspirate is 'dry'; core biopsy shows hypercellular marrow with grade 3 reticulin fibrosis and atypical megakaryocytic clusters. Cytogenetics: new complex karyotype with monosomy 7. Which is the most appropriate next step in disease-directed management?", "options": ["Escalate hydroxyurea dose and add low-dose aspirin", "Start ruxolitinib and defer further planning until spleen size stabilizes", "Proceed to allogeneic hematopoietic stem cell transplantation evaluation", "Begin azacitidine as first-line therapy for post-PV myelofibrosis", "Initiate weekly pegylated interferon alfa-2a for cytoreduction"], "answer": "C", "answer_index": 2, "explanation": "She has post-polycythemia vera myelofibrosis with symptomatic splenomegaly, cytopenias, leukoerythroblastosis, and high-risk features (complex karyotype, monosomy 7), making allogeneic stem cell transplantation the only curative option and the preferred strategy if eligible. Ruxolitinib improves symptoms and spleen size but is not curative; azacitidine and interferon are not standard first-line disease-modifying therapies in high-risk post-PV MF, and hydroxyurea escalation will not address progression.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with symptoms and findings highly suggestive of transformation to post-polycythemia vera myelofibrosis (PPV-MF). These include progressive fatigue, weight loss, early satiety, night sweats, marked splenomegaly, anemia, leukocytosis with left shift, thrombocytopenia, tear-drop cells, nucleated RBCs, leukoerythroblastosis, elevated LDH and uric acid, a dry bone marrow aspirate with hypercellularity, grade 3 reticulin fibrosis, atypical megakaryocytic clusters, and importantly, a new complex karyotype with monosomy 7. Monosomy 7 is a high-risk cytogenetic abnormality associated with a poor prognosis in myeloproliferative neoplasms and their transformations.\n\nLet's analyze the options:\n\nA. Escalate hydroxyurea dose and add low-dose aspirin: Hydroxyurea is a cytoreductive agent, but it is unlikely to be effective in controlling the symptoms and disease progression in advanced myelofibrosis, especially with high-risk cytogenetics. Aspirin is typically used for thrombosis risk in PV, not for managing MF.\n\nB. Start ruxolitinib and defer further planning until spleen size stabilizes: Ruxolitinib is a JAK inhibitor that is effective in managing symptoms and splenomegaly in myelofibrosis. However, given the presence of a high-risk cytogenetic abnormality (monosomy 7) and the potential for transformation to acute myeloid leukemia (AML), deferring further planning is not appropriate. Ruxolitinib is a bridge therapy, not a curative option.\n\nC. Proceed to allogeneic hematopoietic stem cell transplantation evaluation: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative treatment for myelofibrosis, especially in patients with high-risk cytogenetic abnormalities and significant symptoms. The presence of monosomy 7, a complex karyotype, and symptomatic splenomegaly makes this patient a strong candidate for allo-HSCT evaluation. Early evaluation is crucial as it requires donor identification and conditioning.\n\nD. Begin azacitidine as first-line therapy for post-PV myelofibrosis: Azacitidine is a hypomethylating agent used primarily for myelodysplastic syndromes (MDS) and AML. While it can be used in some cases of advanced MF with features of MDS or AML transformation, it is not typically the first-line therapy for symptomatic PPV-MF with high-risk cytogenetics. Allo-HSCT is generally preferred in such cases.\n\nE. Initiate weekly pegylated interferon alfa-2a for cytoreduction: Interferon is another cytoreductive agent that can be used in MPNs. However, its efficacy in advanced myelofibrosis, particularly with high-risk cytogenetics, is limited compared to other options, and it is not the most appropriate next step in this scenario.\n\nConsidering the high-risk features, particularly the monosomy 7 and symptomatic splenomegaly, the most appropriate next step is to evaluate for allogeneic hematopoietic stem cell transplantation, as it offers the best chance for long-term survival and potential cure.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-003", "question": "A 28-year-old G1P0 woman at 33 weeks' gestation presents to the ED with acute dyspnea, pleuritic chest pain, and near syncope. HR 132/min, BP 82/48 mm Hg, RR 30/min, SpO2 89% on 6 L nasal cannula. Bedside echo reveals a dilated RV with McConnell sign and septal flattening. CTA is unavailable; lower-extremity duplex is pending. She is consentable and has no contraindications to thrombolysis. Fetal heart tones are 150 bpm with moderate variability. Which management is most appropriate now?", "options": ["Systemic thrombolysis with weight-based alteplase bolus and infusion", "Urgent catheter-directed thrombolysis with reduced-dose alteplase", "Immediate transfer for surgical embolectomy with cardiopulmonary bypass", "Initiate high-dose unfractionated heparin and defer reperfusion until postpartum", "Administer tenecteplase as a single IV bolus followed by heparin"], "answer": "A", "answer_index": 0, "explanation": "She has high-risk (massive) pulmonary embolism with shock in late pregnancy; systemic thrombolysis is recommended when no absolute contraindications exist, as maternal survival takes priority and pregnancy is only a relative contraindication. Catheter-directed therapy or surgical embolectomy may be considered when thrombolysis is contraindicated or fails, not as first-line; deferring reperfusion is unsafe, and tenecteplase bolus lacks robust pregnancy-specific safety and dosing data compared with standard alteplase protocols.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient presents with signs and symptoms highly suggestive of a massive pulmonary embolism (PE) with hemodynamic instability (hypotension, tachycardia, hypoxia). The bedside echocardiogram findings (dilated RV, McConnell sign, septal flattening) further support right ventricular strain, consistent with a massive PE.\n\nGiven the hemodynamic instability and the availability of consent and no contraindications to thrombolysis, systemic thrombolysis is the most appropriate immediate management.\n\nLet's analyze the options:\n\nA. Systemic thrombolysis with weight-based alteplase bolus and infusion: This is the standard of care for massive PE with hemodynamic instability. Alteplase is a fibrinolytic agent that can rapidly dissolve the clot.\n\nB. Urgent catheter-directed thrombolysis with reduced-dose alteplase: While catheter-directed thrombolysis can be an option for submassive PE or in cases where systemic thrombolysis is contraindicated, systemic thrombolysis is generally preferred for massive PE due to its speed and effectiveness in restoring hemodynamics. Reduced dose might be considered in specific scenarios, but for a hemodynamically unstable patient, full systemic thrombolysis is indicated.\n\nC. Immediate transfer for surgical embolectomy with cardiopulmonary bypass: Surgical embolectomy is reserved for patients with massive PE who fail to respond to thrombolysis or in whom thrombolysis is contraindicated. Transferring the patient for surgery would delay critical treatment.\n\nD. Initiate high-dose unfractionated heparin and defer reperfusion until postpartum: Heparin is an anticoagulant, not a thrombolytic. While anticoagulation is crucial in PE management, it does not address the acute clot burden causing hemodynamic instability. Delaying reperfusion until postpartum would be detrimental to the patient's survival.\n\nE. Administer tenecteplase as a single IV bolus followed by heparin: Tenecteplase is a fibrinolytic agent that can be administered as a single bolus, which can be faster than an alteplase infusion. However, alteplase is more commonly used for massive PE in many guidelines, and the question specifies \"weight-based alteplase bolus and infusion\" as an option. While tenecteplase is a valid thrombolytic, option A describes a standard and effective approach for massive PE. In the context of the provided options, systemic thrombolysis with alteplase is the most direct and appropriate immediate intervention.\n\nConsidering the patient's critical condition and the available options, systemic thrombolysis is the most appropriate immediate management. Option A describes the standard approach for this scenario.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-004", "question": "A 4-year-old boy is brought to the PICU with progressive leg weakness and refusal to walk for 5 days after a viral upper respiratory infection. Exam: flaccid symmetric weakness in legs > arms, areflexia, intact sensation, no bowel/bladder dysfunction, and no cranial nerve involvement. He can lift his head briefly but cannot stand; FVC is 55% predicted. MRI spine is normal. CSF shows protein 42 mg/dL, 3 WBC/µL. Nerve conduction studies show reduced CMAP amplitudes with preserved conduction velocities and distal latencies; sensory studies are normal, and F-waves are absent. Which subtype best describes his neuropathy and has implications for prognosis and treatment response?", "options": ["Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)", "Acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome", "Acute motor and sensory axonal neuropathy (AMSAN)", "Miller Fisher syndrome", "Acute flaccid myelitis related to enterovirus D68"], "answer": "B", "answer_index": 1, "explanation": "Normal conduction velocities with low CMAP amplitudes, preserved sensory responses, and absent F-waves indicate a purely motor axonal process, characteristic of AMAN, which in children often follows infection and may have rapid progression but good recovery with immunotherapy. AIDP would show demyelinating features (slowed velocities, prolonged latencies), AMSAN would have sensory involvement, Miller Fisher presents with ophthalmoplegia/ataxia, and acute flaccid myelitis involves spinal gray matter with MRI abnormalities and asymmetric weakness.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with acute flaccid paralysis following a viral prodrome, which is characteristic of Guillain-Barré syndrome (GBS). The neurological examination reveals flaccid symmetric weakness in the legs greater than the arms, areflexia, and intact sensation, which are classic findings for GBS. The normal MRI spine and CSF findings (mildly elevated protein with normal cell count) are also consistent with GBS.\n\nThe nerve conduction studies (NCS) are crucial for differentiating subtypes of GBS. The findings of reduced compound muscle action potential (CMAP) amplitudes with preserved conduction velocities and distal latencies, normal sensory studies, and absent F-waves strongly suggest an axonal process affecting motor nerves.\n\nLet's analyze the options:\n\nA. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) is the most common subtype of GBS. It is characterized by demyelination of peripheral nerves, leading to slowed nerve conduction velocities and prolonged distal latencies. The NCS findings in this patient (preserved conduction velocities and distal latencies) are not typical of AIDP.\n\nB. Acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome is characterized by damage to the motor axons with relative preservation of myelin and sensory nerves. This leads to reduced CMAP amplitudes with preserved conduction velocities and distal latencies. The absent F-waves are also consistent with axonal damage. This subtype is often associated with antecedent infections, particularly *Campylobacter jejuni*. The clinical presentation and NCS findings in this patient are highly suggestive of AMAN.\n\nC. Acute motor and sensory axonal neuropathy (AMSAN) involves damage to both motor and sensory axons. This would typically manifest with reduced amplitudes in both motor and sensory nerve conduction studies, which is not seen here as sensory studies are normal.\n\nD. Miller Fisher syndrome (MFS) is a variant of GBS characterized by ophthalmoplegia, ataxia, and areflexia. While areflexia is present, the prominent finding is leg weakness, and there is no mention of ophthalmoplegia or ataxia. NCS in MFS can show varying patterns, but the described findings are not typical.\n\nE. Acute flaccid myelitis (AFM) related to enterovirus D68 is a serious condition that causes acute flaccid paralysis, often with a characteristic \"owl's eye\" pattern on MRI of the spinal cord. While the patient has acute flaccid paralysis, the normal MRI spine makes AFM less likely. Furthermore, the NCS findings are more typical of GBS than AFM, which can have variable NCS findings but often shows more widespread involvement.\n\nGiven the clinical presentation and the specific nerve conduction study findings (reduced CMAP amplitudes with preserved conduction velocities and distal latencies, normal sensory studies, absent F-waves), the subtype that best describes this neuropathy is AMAN. AMAN is a subtype of GBS that primarily affects motor axons and has implications for prognosis and treatment response, often responding well to IVIg or plasmapheresis.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-005", "question": "A 47-year-old man with poorly controlled type 2 diabetes and daily alcohol use presents with 10 days of fever, right-sided headache, and progressive confusion. He was treated with oral amoxicillin-clavulanate for presumed sinusitis without improvement. On exam he is disoriented, febrile (38.8°C), with mild left hemiparesis and papilledema. CT head with contrast shows a 3.5-cm ring-enhancing lesion in the right frontal lobe with extensive surrounding edema contiguous with opacified frontal sinus. Emergent dexamethasone and broad-spectrum IV antibiotics are started. Neurocritical care team plans operative management. Which surgical approach is most appropriate now?", "options": ["CT-guided stereotactic needle aspiration of the abscess", "Open craniotomy with complete abscess excision and sinus drainage", "Endoscopic transnasal drainage of the frontal sinus only", "Placement of an external ventricular drain for CSF diversion and observation", "Delay surgical intervention; continue maximal medical therapy for 2 weeks"], "answer": "B", "answer_index": 1, "explanation": "A large frontal lobe abscess contiguous with frontal sinus and mass effect in an immunocompromised host favors open craniotomy with abscess excision plus definitive sinus drainage to eradicate the source and relieve mass effect. Needle aspiration alone risks persistent infection from ongoing sinus seeding; sinus drainage only is insufficient; EVD does not address the mass; delaying surgery risks herniation and neurological decline.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with a large, ring-enhancing lesion in the right frontal lobe with surrounding edema, contiguous with an opacified frontal sinus. This strongly suggests a brain abscess originating from the frontal sinusitis. The progressive neurological deficits (confusion, hemiparesis) and papilledema indicate significant mass effect and increased intracranial pressure.\n\nLet's analyze the options:\n\nA. CT-guided stereotactic needle aspiration: While aspiration can be used for diagnosis and treatment of brain abscesses, a 3.5-cm lesion with extensive edema and contiguous sinus involvement likely requires more definitive management than just aspiration. It might be considered if the lesion were smaller or in a critical location where open resection would be too risky, but given the size and likely source, it's not the *most* appropriate initial approach for definitive treatment.\n\nB. Open craniotomy with complete abscess excision and sinus drainage: This approach allows for direct visualization and complete removal of the abscess capsule, which is crucial for eradicating the infection and reducing the risk of recurrence. It also allows for direct drainage and debridement of the infected frontal sinus, addressing the source of the infection. This is generally considered the gold standard for large, symptomatic brain abscesses with a clear contiguous source.\n\nC. Endoscopic transnasal drainage of the frontal sinus only: While addressing the sinusitis is important, this approach would not directly address the large brain abscess. The abscess itself needs to be evacuated and excised.\n\nD. Placement of an external ventricular drain for CSF diversion and observation: An EVD is indicated for hydrocephalus or significant intracranial hypertension that cannot be managed medically. While the patient has papilledema suggesting increased ICP, the primary problem is the abscess. An EVD alone does not treat the abscess and is usually a temporizing measure or used in conjunction with other treatments.\n\nE. Delay surgical intervention; continue maximal medical therapy for 2 weeks: The patient is presenting with progressive neurological deficits and signs of increased intracranial pressure. Delaying surgical intervention in the face of a large, symptomatic brain abscess can lead to significant morbidity or mortality. Maximal medical therapy (antibiotics and steroids) is important, but surgical drainage is indicated for definitive treatment.\n\nConsidering the size of the abscess, the contiguous spread from the frontal sinus, and the progressive neurological deficits, an open craniotomy with complete abscess excision and sinus drainage offers the most definitive and appropriate surgical management.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-006", "question": "A 66-year-old man with COPD and metastatic non-small cell lung cancer (PD-L1 80%) started pembrolizumab 10 weeks ago. He presents with 4 days of worsening exertional dyspnea and dry cough, afebrile, with O2 saturation 90% on room air. CT pulmonary angiography shows no embolus but reveals new bilateral, patchy ground-glass opacities and reticular changes in the lower lobes with subpleural sparing. There is no infection on extensive workup, BNP is normal, and no cardiac ischemia. He is on no new drugs besides pembrolizumab. How should this complication be graded and managed now?", "options": ["Grade 1 pneumonitis; continue pembrolizumab with close monitoring only", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 0.5 mg/kg/day", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give IV methylprednisolone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give infliximab immediately without steroids"], "answer": "C", "answer_index": 2, "explanation": "He has symptomatic but non-life-threatening immune-related pneumonitis (dyspnea, new infiltrates, no severe hypoxia), corresponding to grade 2; standard management is to hold the checkpoint inhibitor and start systemic steroids at 1-2 mg/kg/day with a prolonged taper. Grade 3 would involve severe symptoms or oxygen requirement; lower steroid doses or continuation of pembrolizumab are inadequate, and infliximab is reserved for steroid-refractory cases, not first-line.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with new-onset dyspnea and cough, along with bilateral ground-glass opacities on CT scan, occurring 10 weeks after starting pembrolizumab. This clinical presentation and imaging findings are highly suggestive of immune-related adverse events (irAEs), specifically pneumonitis, in the context of immunotherapy.\n\nLet's evaluate the grading and management options based on established guidelines for irAEs.\n\n**Grading of Pneumonitis:**\nThe severity of pneumonitis is graded based on symptoms and objective findings.\n*   **Grade 1:** Mild symptoms, no significant impairment of daily activities.\n*   **Grade 2:** Moderate symptoms, limiting instrumental ADL.\n*   **Grade 3:** Severe symptoms, disabling, requiring hospitalization or oxygen.\n\nIn this case, the patient has worsening exertional dyspnea and a dry cough, with O2 saturation of 90% on room air. This indicates a significant respiratory compromise that is likely limiting his daily activities and potentially requires oxygen support. Therefore, this is at least Grade 2 pneumonitis. The presence of new bilateral opacities on CT further supports this.\n\n**Management of Pneumonitis:**\nThe management of irAE-related pneumonitis depends on the grade.\n*   **Grade 1:** Continue the immune checkpoint inhibitor (ICI) with close monitoring.\n*   **Grade 2:** Hold the ICI and initiate systemic corticosteroids. The typical starting dose for Grade 2 pneumonitis is prednisone 0.5-1 mg/kg/day.\n*   **Grade 3:** Permanently discontinue the ICI and initiate high-dose systemic corticosteroids (e.g., IV methylprednisolone 1-2 mg/kg/day, followed by oral prednisone). Infliximab may be considered for refractory cases.\n\nNow let's analyze the options:\n\n*   **A. Grade 1 pneumonitis; continue pembrolizumab with close monitoring only:** This is incorrect because the patient's symptoms (dyspnea, O2 saturation of 90%) and imaging findings suggest at least Grade 2 pneumonitis, not Grade 1.\n\n*   **B. Grade 2 pneumonitis; hold pembrolizumab and start prednisone 0.5 mg/kg/day:** This option correctly identifies the grade as at least Grade 2 and proposes holding pembrolizumab. The starting dose of prednisone at 0.5 mg/kg/day is appropriate for Grade 2 pneumonitis.\n\n*   **C. Grade 2 pneumonitis; hold pembrolizumab and start prednisone 1-2 mg/kg/day:** While holding pembrolizumab is correct, a starting dose of 1-2 mg/kg/day is generally reserved for Grade 3 pneumonitis or more severe Grade 2 cases. For initial Grade 2, 0.5-1 mg/kg/day is more typical.\n\n*   **D. Grade 3 pneumonitis; permanently discontinue pembrolizumab and give IV methylprednisolone 1-2 mg/kg/day:** While the patient has significant symptoms, the description of \"worsening exertional dyspnea\" and O2 saturation of 90% on room air, without mention of hospitalization or severe respiratory failure, might not definitively classify it as Grade 3 without further clinical context. However, if it were Grade 3, this management would be appropriate. The question asks for the *best* option.\n\n*   **E. Grade 3 pneumonitis; permanently discontinue pembrolizumab and give infliximab immediately without steroids:** This is incorrect. Steroids are the first-line treatment for irAE-related pneumonitis. Infliximab is a second-line agent for refractory cases.\n\nComparing options B and C, option B suggests a more conservative initial steroid dose for Grade 2 pneumonitis, which is generally the recommended approach. The patient's condition, while concerning, might not yet meet the criteria for Grade 3 without more severe symptoms or hospitalization. Therefore, treating it as Grade 2 with appropriate management is the most prudent initial step. If the patient does not improve or worsens, escalation to higher steroid doses or consideration of Grade 3 management would be warranted. However, based on the information provided, Grade 2 pneumonitis with initial steroid treatment is the most fitting.\n\nLet's re-evaluate the grading. O2 saturation of 90% on room air, with new bilateral infiltrates, is a significant finding. Some guidelines might consider this Grade 3 if it leads to hospitalization or requires significant intervention. However, the description \"worsening exertional dyspnea and dry cough\" without explicit mention of severe respiratory distress or hospitalization leans towards Grade 2. The key is the management. Holding the drug and starting steroids is crucial for both Grade 2 and 3. The difference lies in the intensity of steroids and whether to permanently discontinue.\n\nConsidering the options, option B provides a reasonable approach for Grade 2 pneumonitis. If the symptoms were more severe, leading to hospitalization or requiring significant oxygen support, Grade 3 would be more appropriate. However, the question asks for the *best* option given the information.\n\nLet's consider the possibility of Grade 3. If it is Grade 3, then option D is the correct management. The distinction between Grade 2 and 3 can be subtle. However, \"worsening exertional dyspnea\" and O2 sat of 90% on room air, while concerning, might not automatically equate to Grade 3 without more severe symptoms.\n\nLet's assume the grading is indeed Grade 2 based on the description. Then option B is the most appropriate. If we consider the possibility of Grade 3, then option D is the management.\n\nLet's look at the typical presentation of Grade 3 pneumonitis. It is often described as severe dyspnea at rest, requiring hospitalization, and significant oxygen support. The current description is \"worsening exertional dyspnea\" and O2 sat 90% on room air. This could be interpreted as Grade 2.\n\nHowever, if we consider the potential for rapid deterioration with immunotherapy-induced pneumonitis, it is often prudent to err on the side of caution. Let's re-examine the options.\n\nOption B: Grade 2 pneumonitis; hold pembrolizumab and start prednisone 0.5 mg/kg/day.\nOption C: Grade 2 pneumonitis; hold pembrolizumab and start prednisone 1-2 mg/kg/day.\n\nIf it is Grade 2, the starting dose of prednisone is typically 0.5-1 mg/kg/day. So, option B is more aligned with the lower end of the recommended range for Grade 2.\n\nLet's consider the possibility that the symptoms are severe enough to be considered Grade 3. If it is Grade 3, then option D is the management.\n\nGiven the ambiguity in definitively classifying it as Grade 2 or 3 solely from the text, let's focus on the management principles. Holding the ICI and starting steroids is paramount. The dose of steroids is the key differentiator.\n\nLet's assume the question intends for us to classify it as Grade 2, as the symptoms are described as \"worsening exertional dyspnea\" rather than severe dyspnea at rest. In that case, option B is the most appropriate initial management.\n\nHowever, if we consider the potential severity and the need for prompt and aggressive treatment of pneumonitis, some might argue for a higher initial dose of steroids even for what appears to be Grade 2, or consider it borderline Grade 3.\n\nLet's review the CT findings: \"new bilateral, patchy ground-glass opacities and reticular changes in the lower lobes with subpleural sparing.\" This is consistent with pneumonitis.\n\nLet's reconsider the grading. O2 saturation of 90% on room air is a significant finding. Many guidelines would consider this to warrant at least Grade 2, and potentially Grade 3 depending on other factors like respiratory rate and need for hospitalization.\n\nIf we assume it is Grade 2, then option B is a reasonable starting point. If we assume it is Grade 3, then option D is the management.\n\nLet's look for subtle clues. The patient is 66 years old with COPD, which might predispose him to more severe respiratory symptoms.\n\nLet's consider the options again. If it is Grade 2, then holding the drug and starting steroids is correct. The dose of steroids is the question. If it is Grade 3, then permanently discontinuing and IV methylprednisolone is correct.\n\nLet's assume the most common interpretation of the symptoms. Worsening exertional dyspnea and O2 sat 90% on room air, without mention of hospitalization or severe distress at rest, is often classified as Grade 2. For Grade 2, holding the ICI and starting prednisone at 0.5-1 mg/kg/day is standard. Option B fits this.\n\nLet's consider if there's a reason to choose a higher dose of steroids for Grade 2. Some guidelines suggest 1 mg/kg/day for Grade 2. Option C suggests 1-2 mg/kg/day for Grade 2, which is on the higher end.\n\nLet's consider the possibility of Grade 3. If it is Grade 3, then option D is the management. The key difference is permanent discontinuation vs. holding.\n\nGiven the options, and the fact that the patient is symptomatic and has objective findings, holding the drug is essential. The question is about the grade and the intensity of treatment.\n\nLet's assume the most conservative but appropriate grading. Grade 2 pneumonitis. Then the choice is between B and C. Option B suggests 0.5 mg/kg/day, and option C suggests 1-2 mg/kg/day. For Grade 2, 0.5-1 mg/kg/day is typical. So, option B is more aligned with the lower end of the recommended range.\n\nHowever, if we consider the potential for rapid progression, some might opt for a slightly higher initial dose.\n\nLet's re-evaluate the grading. O2 saturation of 90% on room air is a significant finding. This could push it towards Grade 3. If it is Grade 3, then option D is the correct management.\n\nLet's consider the possibility that the question is designed to test the recognition of a serious complication requiring aggressive management. Pneumonitis from immunotherapy can be life-threatening.\n\nIf we consider the O2 saturation of 90% on room air as a significant indicator of severity, it might be more appropriate to consider it Grade 3. In that case, option D is the correct management. Permanent discontinuation and IV methylprednisolone are indicated for Grade 3 pneumonitis.\n\nLet's assume the grading is Grade 3 based on the O2 saturation. Then option D is the best choice.\n\nFinal check:\nGrade 3 pneumonitis: Severe symptoms, disabling, requiring hospitalization or oxygen. O2 sat 90% on room air with new bilateral opacities is concerning and could fit this. Management: Permanently discontinue ICI, IV methylprednisolone 1-2 mg/kg/day. This matches option D.\n\nLet's consider if option B could be better. If it's Grade 2, holding and starting prednisone 0.5 mg/kg/day is appropriate. However, the O2 saturation is a strong indicator of severity.\n\nGiven the potential for severe outcomes with immunotherapy-induced pneumonitis, and the O2 saturation of 90%, it is safer to consider it Grade 3 and manage aggressively.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-007", "question": "A 9-year-old girl presents with 2 weeks of progressive headache, morning vomiting, and decline in school performance. Exam reveals papilledema, dysmetria, and truncal ataxia. MRI brain shows an enhancing midline posterior fossa mass infiltrating the cerebellar vermis and roof of the fourth ventricle, with obstructive hydrocephalus. After CSF diversion and near-total resection, histology shows small round blue cells with Homer-Wright rosettes. Molecular profiling reveals WNT-activated medulloblastoma, CTNNB1 mutation, and monosomy 6; no metastatic disease on staging. Which adjuvant treatment strategy is most appropriate?", "options": ["Craniospinal irradiation at standard dose plus multi-agent chemotherapy (high-risk protocol)", "Focal posterior fossa irradiation only plus maintenance oral temozolomide", "Reduced-dose craniospinal irradiation with posterior fossa boost plus chemotherapy (standard-risk protocol)", "Observation only after gross total resection due to favorable WNT subtype", "High-dose chemotherapy with autologous stem cell rescue, without craniospinal irradiation"], "answer": "C", "answer_index": 2, "explanation": "WNT-activated medulloblastoma in a child with non-metastatic disease and near-total resection is standard-risk; current practice uses reduced-dose craniospinal irradiation with posterior fossa boost plus multi-agent chemotherapy to maintain excellent survival while reducing late toxicity. Standard-dose/high-risk protocols are unnecessary; focal RT alone or observation is inadequate due to CSF dissemination risk; high-dose chemo without CSI is investigational and not standard in this scenario.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with a WNT-activated medulloblastoma, which is considered a favorable risk subtype. Key features supporting this include the WNT pathway activation, CTNNB1 mutation, and monosomy 6. Importantly, there is no metastatic disease on staging.\n\nLet's analyze the options:\n\nA. Craniospinal irradiation at standard dose plus multi-agent chemotherapy (high-risk protocol): This is generally reserved for high-risk medulloblastomas, which this patient does not have based on the WNT subtype and absence of metastasis.\n\nB. Focal posterior fossa irradiation only plus maintenance oral temozolomide: While focal irradiation might be considered for very localized disease, the presence of obstructive hydrocephalus and infiltration of the cerebellar vermis and roof of the fourth ventricle suggests a need for more comprehensive treatment. Also, temozolomide is not the standard of care for WNT medulloblastoma.\n\nC. Reduced-dose craniospinal irradiation with posterior fossa boost plus chemotherapy (standard-risk protocol): WNT-activated medulloblastomas, especially without metastatic disease, are generally treated with reduced-dose craniospinal irradiation (CSIR) and a posterior fossa boost, along with chemotherapy. This approach aims to minimize long-term toxicity while effectively treating the disease. The \"standard-risk protocol\" likely refers to a regimen appropriate for this favorable subtype.\n\nD. Observation only after gross total resection due to favorable WNT subtype: While WNT subtype is favorable, observation alone is generally not recommended for medulloblastoma, even in favorable risk groups, due to the risk of recurrence. Adjuvant therapy is typically indicated.\n\nE. High-dose chemotherapy with autologous stem cell rescue, without craniospinal irradiation: High-dose chemotherapy with stem cell rescue is usually reserved for very high-risk or recurrent medulloblastomas, and it is often used in conjunction with, or as an alternative to, standard-dose CSIR in specific high-risk scenarios. It is not the primary approach for a WNT-activated, non-metastatic medulloblastoma.\n\nConsidering the favorable WNT subtype, absence of metastatic disease, and the need for adjuvant treatment to reduce recurrence risk, reduced-dose craniospinal irradiation with a posterior fossa boost and chemotherapy is the most appropriate strategy.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-008", "question": "A 71-year-old woman with hypertension and atrial fibrillation on rivaroxaban is admitted with sudden onset aphasia and right hemiplegia. CT head is negative for hemorrhage; CTA shows left M1 occlusion. Last rivaroxaban dose was 3 hours ago. Labs: creatinine 0.9 mg/dL, normal platelets, INR 1.2, anti-factor Xa level (rivaroxaban-calibrated) 170 ng/mL. She arrives 70 minutes after symptom onset. You are in a center with neurointerventional capability and access to andexanet alfa and 4-factor PCC. What is the best acute reperfusion strategy?", "options": ["Administer IV alteplase followed by mechanical thrombectomy", "Administer andexanet alfa to reverse rivaroxaban, then give IV alteplase", "Proceed directly to mechanical thrombectomy without IV thrombolysis", "Give 4-factor PCC then IV alteplase to offset rivaroxaban effect", "Defer reperfusion therapy and manage with permissive hypertension alone"], "answer": "C", "answer_index": 2, "explanation": "Recent rivaroxaban ingestion with high anti-factor Xa level is a contraindication to IV alteplase, and reversal with andexanet or PCC before tPA is not recommended due to uncertain safety and lack of evidence. In patients with large-vessel occlusion on DOACs, direct mechanical thrombectomy is the preferred reperfusion strategy. Withholding reperfusion altogether is inappropriate given eligibility for thrombectomy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with a large vessel occlusion (M1 segment) stroke, making mechanical thrombectomy the primary reperfusion strategy. However, she is on rivaroxaban, a direct oral anticoagulant (DOA), which complicates the use of IV thrombolysis (alteplase).\n\nLet's analyze the options:\n\n*   **A. Administer IV alteplase followed by mechanical thrombectomy:** While alteplase is a standard treatment for acute ischemic stroke, its use is cautioned in patients on DOAs due to increased bleeding risk. The elevated anti-factor Xa level (170 ng/mL) suggests a significant level of rivaroxaban, further increasing this risk.\n\n*   **B. Administer andexanet alfa to reverse rivaroxaban, then give IV alteplase:** Andexanet alfa is a specific reversal agent for direct factor Xa inhibitors like rivaroxaban. Reversing the anticoagulant effect would mitigate the bleeding risk associated with alteplase. Given the patient's presentation and the availability of andexanet alfa, this is a strong consideration. However, the question asks for the *best acute reperfusion strategy*. While reversing the anticoagulant is important for potentially using alteplase, the primary goal is reperfusion.\n\n*   **C. Proceed directly to mechanical thrombectomy without IV thrombolysis:** Mechanical thrombectomy is indicated for large vessel occlusions. In the context of a patient on a DOA, proceeding directly to mechanical thrombectomy without attempting IV thrombolysis (especially if reversal agents are available or if the risk of IV thrombolysis is deemed too high) is a reasonable approach. The time window for IV alteplase is also critical, and mechanical thrombectomy can be performed even if the patient is outside the typical IV alteplase window but within the mechanical thrombectomy window. Given the M1 occlusion, mechanical thrombectomy is highly likely to be successful.\n\n*   **D. Give 4-factor PCC then IV alteplase to offset rivaroxaban effect:** 4-factor PCC is a reversal agent for vitamin K antagonists (like warfarin) and can have some effect on DOAs, but it's not as specific or as effective as andexanet alfa for factor Xa inhibitors. Andexanet alfa is the preferred reversal agent for rivaroxaban.\n\n*   **E. Defer reperfusion therapy and manage with permissive hypertension alone:** This is incorrect. The patient has a confirmed large vessel occlusion and is a candidate for reperfusion therapy. Permissive hypertension alone is not a reperfusion strategy.\n\nConsidering the options, the most direct and safest reperfusion strategy for a confirmed M1 occlusion in a patient on rivaroxaban, especially with a significant anti-factor Xa level, is to proceed directly to mechanical thrombectomy. While reversing the anticoagulant is a consideration for potentially adding IV alteplase, the primary and most effective reperfusion for an M1 occlusion is mechanical thrombectomy. The risk of bleeding with IV alteplase in this scenario, even after reversal, might still be a concern, and mechanical thrombectomy offers a direct approach to restoring blood flow. The question asks for the *best acute reperfusion strategy*. Mechanical thrombectomy is the definitive reperfusion strategy for M1 occlusions.\n\nHowever, let's re-evaluate the timing and the options. The patient arrives 70 minutes after symptom onset. This is within the window for IV alteplase (typically up to 4.5 hours). The elevated anti-factor Xa level is the main concern for IV alteplase. If andexanet alfa is available, reversing the rivaroxaban would make IV alteplase a safer option to administer *before* or *in conjunction with* mechanical thrombectomy, potentially improving outcomes.\n\nLet's consider the typical management pathways. For a large vessel occlusion, mechanical thrombectomy is the gold standard. If a patient is on a DOAC, the decision to give IV thrombolysis is complex. If reversal agents are available and the decision is made to use IV thrombolysis, it is typically given before mechanical thrombectomy.\n\nThe question asks for the *best acute reperfusion strategy*. This implies the overall approach to restoring blood flow.\n\nIf we consider the possibility of administering IV alteplase, the risk of bleeding needs to be addressed. Reversing the rivaroxaban with andexanet alfa (Option B) would mitigate this risk, allowing for the administration of IV alteplase, which can be beneficial in improving collateral flow and potentially reducing the extent of the infarct before thrombectomy.\n\nLet's reconsider Option C. Proceeding directly to mechanical thrombectomy is a valid strategy, especially if there are concerns about the efficacy or timing of reversal agents, or if the patient is outside the window for IV alteplase. However, in this case, the patient is within the window for IV alteplase, and a reversal agent is available.\n\nThe anti-factor Xa level of 170 ng/mL is significant. Reversing this would be prudent if IV alteplase is to be considered.\n\nLet's think about the sequence. If andexanet alfa is given, it reverses the rivaroxaban. Then, IV alteplase can be administered. This combination aims to maximize reperfusion. Mechanical thrombectomy is then performed.\n\nOption B suggests administering andexanet alfa *then* IV alteplase. This is a plausible strategy to enable the use of IV alteplase safely.\n\nLet's compare B and C again. Option C is safer in terms of avoiding IV thrombolysis altogether if there are significant concerns about bleeding. However, IV alteplase can improve outcomes in select patients. The availability of andexanet alfa makes the use of IV alteplase more feasible.\n\nThe question asks for the *best* strategy. In the context of a large vessel occlusion and the availability of reversal agents, a strategy that combines the benefits of IV thrombolysis with mechanical thrombectomy, while mitigating the risks, would be considered optimal.\n\nGiven the options, Option B, which involves reversing the anticoagulant effect of rivaroxaban with andexanet alfa and then administering IV alteplase, followed by mechanical thrombectomy (implied by the context of neurointerventional capability), aims to provide the most comprehensive reperfusion strategy by leveraging both pharmacological and mechanical approaches safely. The prompt states \"best acute reperfusion strategy,\" and combining safe IV thrombolysis with mechanical thrombectomy is often considered superior to mechanical thrombectomy alone if feasible.\n\nFinal consideration: The anti-factor Xa level is elevated, indicating significant anticoagulation. Reversing this is crucial before administering alteplase. Andexanet alfa is the specific reversal agent. Therefore, reversing the anticoagulant first, then administering alteplase, and then proceeding to mechanical thrombectomy is a logical and potentially optimal strategy.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-009", "question": "A 22-year-old man with sickle cell disease (HbSS) presents with high fever, cough, and pleuritic chest pain. CXR shows new multilobar infiltrates; oxygen saturation is 93% on 2 L/min nasal cannula. Labs: Hgb 7.2 g/dL (baseline 8.5), WBC 18,000/µL, platelets 310,000/µL, reticulocyte count 12%. He is diagnosed with acute chest syndrome and started on broad-spectrum antibiotics, incentive spirometry, and simple transfusion to Hgb 9.5 g/dL. Over 24 hours, oxygen requirement increases to 8 L/min with SpO2 90%, and CXR shows progression to near-complete bilateral airspace opacification. Hgb is now 10.3 g/dL, and he is tachypneic but not yet intubated. Which is the most appropriate next step?", "options": ["Increase simple transfusions to target Hgb 12 g/dL for better oxygen-carrying capacity", "Initiate exchange transfusion targeting HbS <30%", "Start high-dose corticosteroids to reduce pulmonary inflammation", "Add therapeutic anticoagulation for presumed pulmonary embolism", "Intubate and initiate low tidal-volume ventilation, deferring transfusion changes"], "answer": "B", "answer_index": 1, "explanation": "Worsening hypoxemia, radiographic progression, and clinical deterioration despite initial simple transfusion indicate severe acute chest syndrome, for which exchange transfusion to rapidly lower HbS (<30%) is recommended. Further simple transfusion risks hyperviscosity; steroids are controversial and may increase rebound pain; empiric anticoagulation is not first-line without PE evidence; ventilation may be needed but does not replace disease-modifying exchange.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with a severe exacerbation of acute chest syndrome (ACS) in the context of sickle cell disease. Key indicators of severity include increasing oxygen requirements, worsening CXR findings (near-complete bilateral airspace opacification), and a significant drop in hemoglobin despite a simple transfusion. The reticulocyte count of 12% indicates a response to anemia, but the overall picture suggests a rapidly deteriorating pulmonary status.\n\nLet's analyze the options:\n\nA. Increasing simple transfusions to target Hgb 12 g/dL: While improving oxygen-carrying capacity is important, simple transfusions alone may not be sufficient to address the underlying pathophysiology of ACS, especially with such rapid progression. The goal is to reduce sickling and improve oxygenation, which often requires more aggressive intervention.\n\nB. Initiate exchange transfusion targeting HbS <30%: Exchange transfusion is a more effective method than simple transfusion for reducing the proportion of HbS, thereby decreasing sickling and improving oxygen delivery to tissues. Given the rapid deterioration and severe pulmonary involvement, exchange transfusion is a critical intervention to prevent further complications like vaso-occlusion in the lungs. Targeting HbS <30% is a standard goal in severe ACS.\n\nC. Start high-dose corticosteroids: Corticosteroids are generally not recommended in the acute management of ACS due to potential risks of infection and masking of symptoms. While they might have a role in some specific inflammatory conditions, they are not the primary or most appropriate next step in this scenario.\n\nD. Add therapeutic anticoagulation for presumed pulmonary embolism: While pulmonary embolism can occur in sickle cell disease, the primary diagnosis here is ACS, which is a vaso-occlusive crisis in the pulmonary vasculature. Anticoagulation is not the first-line treatment for ACS and could potentially increase bleeding risk.\n\nE. Intubate and initiate low tidal-volume ventilation, deferring transfusion changes: Intubation may become necessary if respiratory failure worsens, but deferring transfusion changes when the patient is rapidly deteriorating and has severe pulmonary involvement is not ideal. Exchange transfusion addresses the underlying sickling process that contributes to ACS.\n\nConsidering the rapid progression of ACS despite initial management, exchange transfusion is the most appropriate next step to aggressively reduce HbS levels and improve oxygenation.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-010", "question": "A 58-year-old man with alcohol-related cirrhosis and portal hypertension is admitted with confusion and generalized tonic-clonic seizures. He has been on valproic acid for epilepsy for 5 years without prior complications. Medications include lactulose and spironolactone. Exam: asterixis, disorientation, jaundice, and mild ascites. Labs: Na 130 mmol/L, K 4.2 mmol/L, BUN 10 mg/dL, creatinine 0.7 mg/dL, AST 65 U/L, ALT 40 U/L, total bilirubin 3.8 mg/dL, INR 1.7, ammonia 96 µmol/L. Serum valproate level is therapeutic, but free valproate level is supratherapeutic; serum carnitine is low, and EEG shows triphasic waves without epileptiform activity. Which is the most appropriate antiseizure management strategy?", "options": ["Continue valproic acid but lower the dose and optimize lactulose therapy", "Discontinue valproic acid and start levetiracetam with IV L-carnitine supplementation", "Switch valproic acid to phenytoin with aggressive albumin replacement", "Add topiramate to valproic acid to improve seizure control", "Continue valproic acid and start rifaximin to reduce ammonia"], "answer": "B", "answer_index": 1, "explanation": "He has cirrhosis with hyperammonemic encephalopathy and high free valproate, consistent with valproate-induced hyperammonemic encephalopathy exacerbated by liver disease and carnitine deficiency; the best approach is to stop valproate, use a non-hepatically metabolized agent such as levetiracetam, and give IV L-carnitine. Dose reduction or adjuncts (lactulose, rifaximin) without discontinuing valproate will not adequately address toxicity; phenytoin is highly protein-bound and hepatically metabolized, and adding topiramate may worsen hyperammonemia.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with confusion, seizures, asterixis, jaundice, ascites, and elevated ammonia, consistent with hepatic encephalopathy superimposed on his alcohol-related cirrhosis. He is also on valproic acid for epilepsy. The key laboratory findings are a therapeutic total valproate level but a supratherapeutic free valproate level, low serum carnitine, and elevated ammonia. The EEG shows triphasic waves, which are characteristic of hepatic encephalopathy, not epileptiform activity.\n\nThe supratherapeutic free valproate level is likely due to the hypoalbuminemia associated with cirrhosis, as valproic acid is highly protein-bound. Low carnitine levels are also a known complication of valproic acid therapy and can contribute to its toxicity. The elevated ammonia level is a direct contributor to hepatic encephalopathy.\n\nLet's analyze the options:\n\nA. Continue valproic acid but lower the dose and optimize lactulose therapy: Lowering the valproic acid dose might reduce the free level, but it could also lead to subtherapeutic levels and breakthrough seizures. While optimizing lactulose is important for hepatic encephalopathy, it doesn't directly address the valproic acid toxicity or the underlying cause of the supratherapeutic free level.\n\nB. Discontinue valproic acid and start levetiracetam with IV L-carnitine supplementation: Levetiracetam is generally considered safe in patients with hepatic impairment and does not rely on protein binding for its efficacy, thus avoiding the issue of supratherapeutic free levels due to hypoalbuminemia. Discontinuing valproic acid addresses the potential toxicity. Supplementing with L-carnitine addresses the documented deficiency and can help mitigate valproic acid toxicity. This option directly addresses the identified problems.\n\nC. Switch valproic acid to phenytoin with aggressive albumin replacement: Phenytoin is also highly protein-bound and can have similar issues with altered free levels in hypoalbuminemia. Aggressive albumin replacement might help, but it's not a primary treatment for valproic acid toxicity and phenytoin might not be the best choice given the hepatic impairment.\n\nD. Add topiramate to valproic acid to improve seizure control: Adding another medication without addressing the underlying valproic acid toxicity and the potential for drug-drug interactions in a patient with cirrhosis is not ideal. Topiramate can also have cognitive side effects, which could worsen the confusion.\n\nE. Continue valproic acid and start rifaximin to reduce ammonia: Rifaximin is used to reduce ammonia production by gut bacteria and is a standard treatment for hepatic encephalopathy. However, it does not address the supratherapeutic free valproate level or the low carnitine. Continuing valproic acid at a dose that results in supratherapeutic free levels is risky.\n\nConsidering the supratherapeutic free valproate level due to hypoalbuminemia, the low carnitine, and the need for a safe and effective antiseizure medication in the context of cirrhosis, discontinuing valproic acid and switching to levetiracetam, along with L-carnitine supplementation, is the most appropriate strategy.\n\nThe final answer is $\\boxed{B}$."}]